英國非專利藥品市場：市場機會及課題 是由出版商Espicom Business Intelligence在2007年06月所出版的。
這份英文市場調查報告書包含160 PAGES 價格從美金1390起跳。
英國非專利藥品市場創下24億英鎊的市場規模紀錄。2005年在處方箋藥當中超過59%是非專利藥品，其市場價值佔整體的26%。
提供製藥、醫療機器市場相關具有權威的資訊的市調公司 Espicom Business Intelligence（總公司：England），出版了一本關於英國非專利藥品市場機會及課題的分析報告書"Opportunities and Challenges for Generic Drugs in the UK"。
本報告書內容包括：英國醫療系統及政治・經濟環境分析、藥品市場中非專利藥品的定位、市場結構、償付制度、價格動向、相關法規限制、非專利藥品市場的市場資料、至2012年為止的市場預測、主要相關業者介紹等。內容綱要摘記如下：
介紹
市場背景
英國非專利藥品市場
- 在藥品市場中的定位
- 市場結構
- 償付
- 價格
- 無商標非專利藥品的價格
- 非專利藥品的償付機制：2005年
- 主要藥品價格水準降到與非專利藥品相同
- DOH的諮詢建議
- 藥品相關規範
- 智慧財產
- 處方箋藥市場
- 非專利藥品的市場規模
- 成長前景預測
- 國内產業概要
- 交易總值
- 英國的交易金額
- 營業收益
- 淨利
- 員工
- 平均每位員工的銷售業績
- 主要企業
- 生產許可
- 商社
- 批發業者
- 零售業者
附錄1：主要專利到期的藥品
附錄2：英國施德丁類藥市場中非專利藥品利用的擴大
附錄3：英國PPI市場中的非專利藥品
Abstract
The UK generic market is one of the world' s largest in terms of both size and
generic penetration. This report provides sets generics into the context of
the pharmaceutical market as a whole, assesses the market outlook and provides
forecasts to 2012. It includes an insightful review of major players in the
market and detailed listing of leading products including prescription data,
price companisons and marketing authorisations. All you need to know for an
informed business judgement!
The £2.4 billion UK generics market is one of the world' s largest in
terms of both size and generic penetration. In 2005 over 59% of prescriptions
were dispensed as generics, accounting for 26% of the market value. But fierce
competition and price pressure are turning up the heat. How will the market
continue to grow?
Key areas addressed:
- 5-Year market forecast to 2012 for value
- The generics market in context of the whole pharmaceutical industry
- Pricing issues and reimbursement
- Political, legal and economic assessment
- Insightful review of 18 major domestic and foreign players in the market
- Detailed listing of 18 leading products including prescription data, price
comparisons and marketing authorisations
- Focus on developing generic markets for statins and proton pump inhibitors
The UK generics market has proved a difficult operating environment in recent
years. Many established suppliers have experienced declining sales and
profitability, due to a number of factors. On the one hand, the market is
relatively easy to enter, leading to rapid and fierce price competition for
major drugs. On the other, the UK government keeps a close watch on generic
drug pricing, and has proved willing to reduce prices for a number of products
in recent years.
As in the wider global market, there are signs of ongoing industry
consolidation. Teva and IVAX both have a strong presence in the UK, making
Teva the clear market leader since its 2006 purchase of IVAX. One new
development is the growing arrival of US companies in the market with control
of Pliva going to Barr Laboratories in 2006, and Generics (UK) set to become
part of Mylan in 2007. There are no major UK-owned generic manufacturers.
But who are the leading players and what are their strengths? What barriers to
market entry exist? What marketing authorisations have recently been issued,
and to whom? What will be the operating and regulatory environment for
companies? The answers to these and many other questions can be found in this
160-page management report Opportunities and Challenges for Generic Drugs in
the UK.
Table of Contents
Foreword
Introduction
Background to the Market
- Geography
- Political Overview
- Economic Overview
- Demographics
- The UK Healthcare System
- Organisation
- Healthcare expenditure
- Hospital beds
- Medical personnel
The UK Generics Market
- In Context: the UK Pharmaceutical Market
- Market Structure
- Reimbursement
- Pricing: the PPRS
- Unbranded Generic Pricing
- 2005 generics reimbursement scheme
- Generic price reductions for four major drugs
- DOH Holds consultations regarding branded generics in the PPRS
- Regulation of Pharmaceuticals
- Intellectual Property
- Supplementary Protection Certificates
- Prescription Medicines Market
- Generic Market Size
- Outlook for Future Growth
- Investigations into price fixing
- Department of Health
- Ranbaxy and Merck settle DOH claims
- Serious Fraud Office
- Overview of the Domestic Industry
- Total Turnover
- UK Turnover
- Operating Profit
- Net Profit
- Employees
- Sales per Employee
- Leading Players in the Market
- Actavis UK Ltd
- Actavis worldwide
- Actavis in the UK
- Products on the UK market
- Financial indicators
- Arrow Generics Ltd
- Products on the UK market
- Financial indicators
- Bristol Laboratories
- Products on the UK Market
- Financial indicators
- Crescent Pharma
- Products on the UK market
- Financial indicators
- Dr Reddy' s Laboratories (UK) Ltd
- Dr Reddy' s worldwide
- UK operations
- Financial indicators
- Focus Pharmaceuticals
- Products in the UK
- Financial Indicators
- Generics (UK) Ltd
- Merck Generics worldwide
- UK Operations
- Products in the UK market
- Financial indicators
- Genus Pharmaceuticals
- Products
- Financial indicators
- Goldshield Pharmaceuticals Ltd
- Goldshield Group
- Products
- Financial indicators
- Kent Pharmaceuticals
- Products
- Financial indicators
- Perrigo UK Ltd
- Products
- Financial indicators
- Pliva Pharma Ltd
- Pliva worldwide
- Pliva in the UK
- Financial indicators
- Ranbaxy (UK) Ltd
- Ranbaxy worldwide
- Ranbaxy in the UK
- Financial indicators
- ratiopharm UK
- ratiopharm worldwide
- ratiopharm in the UK
- Financial indicators
- Rosemont Pharmaceuticals
- Products
- Financial indicators
- Sandoz
- Sandoz worldwide
- Sandoz in the UK
- Products
- Financial indicators
- Teva UK
- Teva worldwide
- Teva in the UK
- Financial indicators
- Winthrop Pharmaceuticals
- Winthrop worldwide
- Winthrop in the UK
- Products
- Financial indicators
- Wockhardt UK Ltd
- Wockhardt worldwide
- Wockhardt in the UK
- Products
- Financial indicators
- Marketing Authorisations in 2006
- Trading Companies
- Wholesaling
- AAH Pharmaceuticals Ltd
- Alliance Boots (formerly Alliance Unichem)
- Exclusive Distribution Deal with Pfizer
- Mawdsleys
- Phoenix Healthcare Distribution Ltd
- Retailing
- Major Pharmacy Chains
- Lloyds Pharmacy
- Superdrug
Appendix 1: Analysis of Leading Patent-Expired Drugs
- Amisulpride
- Risperidone
- Ramipril
- Glimepiride
- Ondansetron
- Sumatriptan
- Amlodipine
- Citalopram
- Fluconazole
- Gabapentin
- Lamotrigine
- Meloxicam
- Meloxicam
- Sertraline
- Tamsulosin
- Terbinafine
Appendix 2: Rising Use of Generics in the UK Statins Market
- Market Developments
- Atorvastatin
- Fluvastatin
- Pravastatin
- Rosuvastatin
- Simvastatin
Appendix 3: Generics in the UK PPI Market
- Esomeprazole
- Lansoprazole
- Omeprazole
- Pantoprazole
- Rabeprazole sodium
Appendix 4: Sources
- Espicom Sources
- UK Government Sources
- Industry Sources
Appendix 5: DIRECTORY
- Regulators
- Trade Bodies
- Manufacturers
